The oft-recommended de-prescribing or ‘drug holidays’ from anti-resorptive therapies are not advisable for many patients at risk of fragility fractures, according to osteoporosis experts. A MJA editorial by Professor John Eisman and Associate Professor Christopher White said the benefit of bisphosphonates on bone might persist for 1-2 years beyond cessation of therapy but was variable. ...
Already a member?
Enter your email to keep reading.